China Isotope & Radiation Corp
HKEX:1763
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (0.6), the stock would be worth HK$15.11 (20% downside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.7 | HK$18.82 |
0%
|
| 3-Year Average | 0.6 | HK$15.11 |
-20%
|
| 5-Year Average | 0.7 | HK$18.87 |
+0%
|
| Industry Average | 4.4 | HK$113.58 |
+504%
|
| Country Average | 2.8 | HK$71.32 |
+279%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
HK$5.9B
|
/ |
Jan 2026
¥7.2B
|
= |
|
|
HK$5.9B
|
/ |
Dec 2026
¥8.1B
|
= |
|
|
HK$5.9B
|
/ |
Dec 2027
¥8.9B
|
= |
|
|
HK$5.9B
|
/ |
Dec 2028
¥9.8B
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
C
|
China Isotope & Radiation Corp
HKEX:1763
|
6B HKD | 0.7 | 16 | |
| JP |
|
Hoya Corp
TSE:7741
|
9.4T JPY | 10.3 | 37.6 | |
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
58.4B USD | 0 | 0 | |
| CH |
|
Alcon AG
SIX:ALC
|
28.4B CHF | 3.4 | 36.3 | |
| DK |
|
Coloplast A/S
CSE:COLO B
|
88.8B DKK | 3.3 | 22.7 | |
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
12.6B USD | 3.1 | 30.6 | |
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.6B USD | 1.1 | -15.6 | |
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.1B GBP | 2.2 | 31.2 | |
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
37.9B CNY | 8.3 | 23 | |
| CN |
|
Intco Medical Technology Co Ltd
SZSE:300677
|
37.3B CNY | 3.8 | 21.9 | |
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
8.1T KRW | 95.7 | -36.5 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.5 |
| Median | 2.8 |
| 70th Percentile | 5.4 |
| Max | 5 034 353.9 |
Other Multiples
China Isotope & Radiation Corp
Glance View
China Isotope & Radiation Corp. engages in the research, development, manufacturing and sale of diagnostic and therapeutic radiopharmaceuticals and radioactive source products for medical and industrial applications. The company is headquartered in Beijing, Beijing. The company went IPO on 2018-07-06. The firm also provides radiation sterilization services. The firm is also involved in the design, manufacture and installation of Gama ray irradiation devices. The firm opeartes its businesse mainly through four segments, including the Pharmaceuticals segment, the Radiological Products segment, the Irradiation segment and the Independent Medical Laboratory Services and Others segment, with the Pharmaceuticals segment as the core segment. The Pharmaceuticals segment is engaged in the development, manufacture and sale of radiopharmaceuticals, the Kit for Urea Breath Test and testing instruments, as well as in vitro immunodiagnostic reagents and boxes for imaging diagnosis and treatment.
